Phase 4 N=162 Randomized Triple-blind Prevention

1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy

Kidney Failure

Bottom Line

View on ClinicalTrials.gov: NCT00748072 ↗

Enrolled (actual)

162

Serious AEs

0.0%

Results posted

Jan 2015

Primary outcome: Primary: The Primary Outcome Measure Was the Incidence of Post-biopsy Bleeding Complications. — 25; 11 participants — p=0.01

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: DDAVP (Drug); saline solution (Drug)
Age: Pediatric, Adult, Older Adult · 16+ yrs
Sex: All
Sponsor: University of Bari
Primary completion: Aug 2009

Outcome Measures

Outcome	Result	p-value
PRIMARY The Primary Outcome Measure Was the Incidence of Post-biopsy Bleeding Complications.	25; 11	0.01 sig

Summary

The investigators evaluated the effect of pre-biopsy treatment with 1-deamino-8-D-arginine (DDAVP) on the incidence of post-biopsy bleeding complications. This is a IV phase single centre, double blind, randomized controlled study in patients, with acute and chronic nephropathy, undergoing ultrasound-guided percutaneous renal biopsy.

Eligibility Criteria

Inclusion Criteria

Males or females > 16 and 1.5 mg/dl and/or creatinine clearance < 60 ml/min

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00748072). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.